The value of effective public tuberculosis treatment: An analysis of opportunity costs associated with multidrug resistant tuberculosis in Latvia

Thaddeus L. Miller, Andra Cirule, Fernando A. Wilson, Timothy H. Holtz, Vija Riekstina, Kevin P. Cain, Patrick K. Moonan, Vaira Leimane

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: A challenge to effective protection against tuberculosis is to sustain expensive and complex treatment public programs. Potential consequences of program failure include acquired drug resistance, poor patient outcomes, and potentially much higher system costs, however. In contrast, effective efforts have value illustrated by impacts they prevent. We compared the healthcare costs and treatment outcomes among multidrug-resistant tuberculosis (MDR-TB) and non MDR-TB patients in Latvia to identify benefits or costs associated with both.Methods: We measured and compared costs, healthcare utilization, and outcomes for patients who began treatment through Latvia's TB control program in 2002 using multivariate regression analysis and negative binomial regression.Results: We analyzed data for 92 MDR-TB and 54 non MDR-TB patients. Most (67%) MDR-TB patients had history of prior tuberculosis treatment. MDR-TB was associated with lower cure rates (71% vs. 91%) and greater resource utilization. MDR-TB treatment cost almost $20,000 more than non MDR-TB.Conclusion: Up to 2/3 of MDR-TB treated in our sample was preventable at a potential savings of over $1.3 million in healthcare resources as well as substantial individual health.

Original languageEnglish (US)
Article number9
JournalCost Effectiveness and Resource Allocation
Volume11
Issue number1
DOIs
StatePublished - Apr 17 2013

Fingerprint

Latvia
Multidrug-Resistant Tuberculosis
Tuberculosis
Costs and Cost Analysis
Health Care Costs
Therapeutics
Drug Resistance
Cost-Benefit Analysis
Multivariate Analysis
Regression Analysis
Delivery of Health Care

Keywords

  • Cost analysis
  • Evidence based policy
  • Health economics
  • Tuberculosis cost

ASJC Scopus subject areas

  • Health Policy

Cite this

The value of effective public tuberculosis treatment : An analysis of opportunity costs associated with multidrug resistant tuberculosis in Latvia. / Miller, Thaddeus L.; Cirule, Andra; Wilson, Fernando A.; Holtz, Timothy H.; Riekstina, Vija; Cain, Kevin P.; Moonan, Patrick K.; Leimane, Vaira.

In: Cost Effectiveness and Resource Allocation, Vol. 11, No. 1, 9, 17.04.2013.

Research output: Contribution to journalArticle

Miller, Thaddeus L. ; Cirule, Andra ; Wilson, Fernando A. ; Holtz, Timothy H. ; Riekstina, Vija ; Cain, Kevin P. ; Moonan, Patrick K. ; Leimane, Vaira. / The value of effective public tuberculosis treatment : An analysis of opportunity costs associated with multidrug resistant tuberculosis in Latvia. In: Cost Effectiveness and Resource Allocation. 2013 ; Vol. 11, No. 1.
@article{6b0e229f4222454799e43531f6a4bb89,
title = "The value of effective public tuberculosis treatment: An analysis of opportunity costs associated with multidrug resistant tuberculosis in Latvia",
abstract = "Background: A challenge to effective protection against tuberculosis is to sustain expensive and complex treatment public programs. Potential consequences of program failure include acquired drug resistance, poor patient outcomes, and potentially much higher system costs, however. In contrast, effective efforts have value illustrated by impacts they prevent. We compared the healthcare costs and treatment outcomes among multidrug-resistant tuberculosis (MDR-TB) and non MDR-TB patients in Latvia to identify benefits or costs associated with both.Methods: We measured and compared costs, healthcare utilization, and outcomes for patients who began treatment through Latvia's TB control program in 2002 using multivariate regression analysis and negative binomial regression.Results: We analyzed data for 92 MDR-TB and 54 non MDR-TB patients. Most (67{\%}) MDR-TB patients had history of prior tuberculosis treatment. MDR-TB was associated with lower cure rates (71{\%} vs. 91{\%}) and greater resource utilization. MDR-TB treatment cost almost $20,000 more than non MDR-TB.Conclusion: Up to 2/3 of MDR-TB treated in our sample was preventable at a potential savings of over $1.3 million in healthcare resources as well as substantial individual health.",
keywords = "Cost analysis, Evidence based policy, Health economics, Tuberculosis cost",
author = "Miller, {Thaddeus L.} and Andra Cirule and Wilson, {Fernando A.} and Holtz, {Timothy H.} and Vija Riekstina and Cain, {Kevin P.} and Moonan, {Patrick K.} and Vaira Leimane",
year = "2013",
month = "4",
day = "17",
doi = "10.1186/1478-7547-11-9",
language = "English (US)",
volume = "11",
journal = "Cost Effectiveness and Resource Allocation",
issn = "1478-7547",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - The value of effective public tuberculosis treatment

T2 - An analysis of opportunity costs associated with multidrug resistant tuberculosis in Latvia

AU - Miller, Thaddeus L.

AU - Cirule, Andra

AU - Wilson, Fernando A.

AU - Holtz, Timothy H.

AU - Riekstina, Vija

AU - Cain, Kevin P.

AU - Moonan, Patrick K.

AU - Leimane, Vaira

PY - 2013/4/17

Y1 - 2013/4/17

N2 - Background: A challenge to effective protection against tuberculosis is to sustain expensive and complex treatment public programs. Potential consequences of program failure include acquired drug resistance, poor patient outcomes, and potentially much higher system costs, however. In contrast, effective efforts have value illustrated by impacts they prevent. We compared the healthcare costs and treatment outcomes among multidrug-resistant tuberculosis (MDR-TB) and non MDR-TB patients in Latvia to identify benefits or costs associated with both.Methods: We measured and compared costs, healthcare utilization, and outcomes for patients who began treatment through Latvia's TB control program in 2002 using multivariate regression analysis and negative binomial regression.Results: We analyzed data for 92 MDR-TB and 54 non MDR-TB patients. Most (67%) MDR-TB patients had history of prior tuberculosis treatment. MDR-TB was associated with lower cure rates (71% vs. 91%) and greater resource utilization. MDR-TB treatment cost almost $20,000 more than non MDR-TB.Conclusion: Up to 2/3 of MDR-TB treated in our sample was preventable at a potential savings of over $1.3 million in healthcare resources as well as substantial individual health.

AB - Background: A challenge to effective protection against tuberculosis is to sustain expensive and complex treatment public programs. Potential consequences of program failure include acquired drug resistance, poor patient outcomes, and potentially much higher system costs, however. In contrast, effective efforts have value illustrated by impacts they prevent. We compared the healthcare costs and treatment outcomes among multidrug-resistant tuberculosis (MDR-TB) and non MDR-TB patients in Latvia to identify benefits or costs associated with both.Methods: We measured and compared costs, healthcare utilization, and outcomes for patients who began treatment through Latvia's TB control program in 2002 using multivariate regression analysis and negative binomial regression.Results: We analyzed data for 92 MDR-TB and 54 non MDR-TB patients. Most (67%) MDR-TB patients had history of prior tuberculosis treatment. MDR-TB was associated with lower cure rates (71% vs. 91%) and greater resource utilization. MDR-TB treatment cost almost $20,000 more than non MDR-TB.Conclusion: Up to 2/3 of MDR-TB treated in our sample was preventable at a potential savings of over $1.3 million in healthcare resources as well as substantial individual health.

KW - Cost analysis

KW - Evidence based policy

KW - Health economics

KW - Tuberculosis cost

UR - http://www.scopus.com/inward/record.url?scp=84876084031&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876084031&partnerID=8YFLogxK

U2 - 10.1186/1478-7547-11-9

DO - 10.1186/1478-7547-11-9

M3 - Article

C2 - 23594422

AN - SCOPUS:84876084031

VL - 11

JO - Cost Effectiveness and Resource Allocation

JF - Cost Effectiveness and Resource Allocation

SN - 1478-7547

IS - 1

M1 - 9

ER -